|
May 13
|
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript
|
|
May 11
|
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years
|
|
May 10
|
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 10
|
Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
|
|
May 9
|
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 9
|
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
|
|
May 2
|
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 11
|
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 26
|
Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
|
|
Mar 22
|
Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
|
|
Mar 22
|
Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
|
|
Mar 21
|
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
|
|
Mar 21
|
Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
|
|
Mar 20
|
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
|
|
Mar 19
|
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
|
|
Mar 19
|
Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
|
|
Mar 19
|
UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study
|
|
Mar 19
|
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
|
|
Mar 12
|
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
|